---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-012056"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2022-03-29T23:59:59+00:00"
generated_at: "2026-06-26T14:24:22.627033+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS reports 2021 net loss of $32.9M; BREXAFEMME revenues $1.1M in launch year

## Summary
- BREXAFEMME net product revenue $1.1M full-year, $0.6M Q4; cost of product revenue $0.3M full-year.
- Net loss $32.9M ($1.25/share) for FY2021 vs $55.2M ($5.15/share) in FY2020.
- Cash $104.5M at year-end; projected runway into Q2 2023; plus $9.7M non-dilutive in early 2022.
- Positive Phase 3 CANDLE for rVVC (65.4% vs 53.1% placebo, p=0.02); sNDA filing Q2 2022.
- Initiating MARIO Phase 3 for invasive candidiasis; Orphan Medicinal Product Designation from EMA.

## SEC filing metadata
- accession: 0001564590-22-012056
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2022-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000156459022012056/0001564590-22-012056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000156459022012056/scyx-8k_20220329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-012056
- JSON: https://secwatch.observer/filing/0001564590-22-012056.json
- Plain text: https://secwatch.observer/filing/0001564590-22-012056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.